Ben Greenfield Life

Urolithin A has a biologically plausible mechanism through the clearance of damaged mitochondria, and small human studies show cautiously positive signals for mitochondrial health and muscular endurance. However, the claim goes beyond the available evidence: effects on systemic inflammation in humans have not been demonstrated in the studies, and the research comes largely from the manufacturer itself, without independent confirmation. The specific idea of 'recharging mitochondria in immune cells' has not yet been tested in humans.

Urolithin A does indeed have a plausible mechanism of action through the clearance of damaged mitochondria, which is what mitophagy is. That mechanism is also the starting point in research into this supplement. However, 'stimulates mitophagy' presents this as an established fact, whereas the evidence in humans is still limited and the studies have largely been funded by the manufacturer without independent confirmation. The claim points in the right direction, but goes beyond what the current evidence firmly supports.

The fact that the thymus shrinks and consequently produces fewer new T-cells, causing the immune system to decline with age, is well documented and broadly confirmed by human studies. However, 'around the age of twenty' as a starting point is stated more precisely than the research supports: the findings describe a gradual process without specifying an exact age of onset. The direction of the claim is correct, but that precise threshold of twenty years cannot be substantiated.

Research shows that magnesium L-threonate (MgT) reaches the brain more effectively than common forms of magnesium, and that small human studies show cautiously positive effects on memory and cognition. The claim regarding crossing the blood-brain barrier is therefore supported. However, the specific mechanism mentioned in the claim, namely increasing synaptic plasticity in the hippocampus, comes from animal research and has not yet been convincingly demonstrated in humans. The evidence for such a categorical claim remains too limited.

Population research offers tentative indications that low doses of lithium, such as those found in drinking water, are associated with less cognitive decline and possibly beneficial health effects. However, the claim that higher lithium levels correlate with lower all-cause mortality goes beyond what the available research can confirm with certainty: the results are mixed and the studies are preliminary in nature. There is no strong evidence that this association holds for the broad category of all causes of death.

That gene therapy aimed at telomere lengthening works in principle has been demonstrated in cell and animal studies: telomerase can compensate for telomere shortening and thus keep telomeres longer. In humans, however, clinical evidence is largely lacking, and there is a serious safety risk: the same mechanism that allows cells to survive longer can also fuel cancer cells. The claim is therefore correct in terms of what is biologically possible, but it overlooks the fact that 'actually lengthening telomeres in the human body' has not yet been properly proven outside the laboratory.

CT studies do indeed show that greater muscle mass and higher muscle density around the chest and upper back are associated with fewer heart attacks and lower mortality, even in people with vascular plaque. However, this is observational research: it has not been proven that the muscles are the cause. Muscle mass is also an indicator of fitness and overall health in a broader sense.